Supernus Pharmaceuticals merges with Indivior
- Merger agreement approved by shareholders
- 48,249,532 votes for merger
- 32,688,410 votes for executive compensation
SUPN
SUPERNUS PHARMACEUTICALS, INC. SEC filings
Every EDGAR filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN), newest first, with AI summaries and stories.
- Ticker
- SUPN
- CIK
- 1356576
- Sector
- Biotech and pharma
- Latest filing
- 3d
Next: earnings expected ~Nov 5 · 10-Q expected ~Nov 5 (deadline Nov 9)
Filings
8-KSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 425SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE Supernus Pharmaceuticals files Form 425
- Filed on 2026-10-06
- Amends proxy statement for merger with Indivior
- Includes updated financial analysis from Cantor Fitzgerald
DEFA14ASUPERNUS PHARMACEUTICALS, INC.SUPNLIVE Supernus Pharmaceuticals announces merger updates
- Supernus and Indivior merge on Oct 15, 2026
- Cantor Fitzgerald adjusted for cash and debt in merger analysis
- Supernus shares valued at $50.55 to $59.50
DEFM14ASUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 4SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 5 insider filings
Jonathan Rubin, insider filing for SUPN
Show all 5
- 4Insider filing for SUPN
- 4Insider filing for SUPN
- 4Insider filing for SUPN
- 4Insider filing for SUPN
- 4Insider filing for SUPN
Jonathan Rubin, reporting
SCHEDULE 13G/ASUPERNUS PHARMACEUTICALS, INC.SUPNLIVE Ownership stake disclosure by MILLENNIUM MANAGEMENT LLC (amended)
MILLENNIUM MANAGEMENT LLC, filed by
425SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE Indivior Pharmaceuticals, Inc., filed by
DEFA14ASUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 425SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 8-KSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE DEFA14ASUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 425SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 8-KSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 10-QSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 8-KSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE DEFA14ASUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 425SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 8-KSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 4SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 5 insider filings
Jack A. Khattar, insider filing for SUPN
Show all 5
- 4Insider filing for SUPN
- 4Insider filing for SUPN
- 4Insider filing for SUPN
- 4Insider filing for SUPN
- 4Insider filing for SUPN
Jack A. Khattar, reporting
8-KSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE S-8SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 8-KSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 8-KSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 10-QSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 8-KSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE ARSSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE DEFA14ASUPERNUS PHARMACEUTICALS, INC.SUPNLIVE DEF 14ASUPERNUS PHARMACEUTICALS, INC.SUPNLIVE SCHEDULE 13GSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE Ownership stake disclosure by VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC, filed by
SCHEDULE 13GSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE Ownership stake disclosure by VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC, filed by
8-KSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 8-KSUPERNUS PHARMACEUTICALS, INC.SUPNLIVE SCHEDULE 13G/ASUPERNUS PHARMACEUTICALS, INC.SUPNLIVE Ownership stake disclosure by VANGUARD GROUP INC (amended)
VANGUARD GROUP INC, filed by
4SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE Padmanabh P. Bhatt, insider filing for SUPN
Padmanabh P. Bhatt, reporting
144SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE Padmanabh P. Bhatt, planned sale of SUPN shares
Padmanabh P. Bhatt, reporting
144SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE Padmanabh P. Bhatt, planned sale of SUPN shares
Padmanabh P. Bhatt, reporting
4SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE 2 insider filings
Jack A. Khattar, insider filing for SUPN
Show all 2
- 4Insider filing for SUPN
- 4Insider filing for SUPN
Jack A. Khattar, reporting
144SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE Jack A. Khattar, planned sale of SUPN shares
Jack A. Khattar, reporting
144SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE Frederick M. Hudson, planned sale of SUPN shares
Frederick M. Hudson, reporting
144SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE William Todd Horich, planned sale of SUPN shares
William Todd Horich, reporting
3SUPERNUS PHARMACEUTICALS, INC.SUPNLIVE William Todd Horich, new insider at SUPN
William Todd Horich, reporting